2015-08602. Availability of an Environmental Assessment for Field Testing a Marek's Disease-Newcastle Disease Vaccine, Serotype 3, Live Marek's Disease Vector  

  • Start Preamble Start Printed Page 19955

    AGENCY:

    Animal and Plant Health Inspection Service, USDA.

    ACTION:

    Notice of availability.

    SUMMARY:

    We are advising the public that the Animal and Plant Health Inspection Service has prepared an environmental assessment concerning authorization to ship for the purpose of field testing, and then to field test, an unlicensed Marek's disease-Newcastle disease vaccine, serotype 3, live Marek's disease vector. The environmental assessment, which is based on a risk analysis prepared to assess the risks associated with the field testing of this vaccine, examines the potential effects that field testing this veterinary vaccine could have on the quality of the human environment. Based on the risk analysis and other relevant data, we have reached a preliminary determination that field testing this veterinary vaccine will not have a significant impact on the quality of the human environment, and that an environmental impact statement need not be prepared. We intend to authorize shipment of this vaccine for field testing following the close of the comment period for this notice unless new substantial issues bearing on the effects of this action are brought to our attention. We also intend to issue a U.S. Veterinary Biological Product license for this vaccine, provided the field test data support the conclusions of the environmental assessment and the issuance of a finding of no significant impact and the product meets all other requirements for licensing.

    DATES:

    We will consider all comments that we receive on or before May 14, 2015.

    ADDRESSES:

    You may submit comments by either of the following methods:

    Supporting documents and any comments we receive on this docket may be viewed at http://www.regulations.gov/​#!docketDetail;​D=​APHIS-2015-0002 or in our reading room, which is located in room 1141 of the USDA South Building, 14th Street and Independence Avenue SW., Washington, DC. Normal reading room hours are 8 a.m. to 4:30 p.m., Monday through Friday, except holidays. To be sure someone is there to help you, please call (202) 799-7039 before coming.

    Start Further Info

    FOR FURTHER INFORMATION CONTACT:

    Dr. Donna Malloy, Operational Support Section, Center for Veterinary Biologics, Policy, Evaluation, and Licensing, VS, APHIS, 4700 River Road Unit 148, Riverdale, MD 20737-1231; phone (301) 851-3426, fax (301) 734-4314.

    For information regarding the environmental assessment or the risk analysis, or to request a copy of the environmental assessment (as well as the risk analysis with confidential business information removed), contact Dr. Patricia L. Foley, Risk Manager, Center for Veterinary Biologics, Policy, Evaluation, and Licensing, VS, APHIS, 1920 Dayton Avenue, P.O. Box 844, Ames, IA 50010; phone (515) 337-6100, fax (515) 337-6120.

    End Further Info End Preamble Start Supplemental Information

    SUPPLEMENTARY INFORMATION:

    Under the Virus-Serum-Toxin Act (21 U.S.C. 151 et seq.), a veterinary biological product must be shown to be pure, safe, potent, and efficacious before a veterinary biological product license may be issued. A field test is generally necessary to satisfy prelicensing requirements for veterinary biological products. Prior to conducting a field test on an unlicensed product, an applicant must obtain approval from the Animal and Plant Health Inspection Service (APHIS), as well as obtain APHIS' authorization to ship the product for field testing.

    To determine whether to authorize shipment and grant approval for the field testing of the unlicensed product referenced in this notice, APHIS considers the potential effects of this product on the safety of animals, public health, and the environment. Using the risk analysis and other relevant data, APHIS has prepared an environmental assessment (EA) concerning the field testing of the following unlicensed veterinary biological product:

    Requester: Merial, Inc.

    Product: Marek's Disease-Newcastle Disease Vaccine, Serotype 3, Live Marek's Disease Vector.

    Possible Field Test Locations: Arkansas, Georgia, Indiana, Iowa, Missouri, Ohio, Oklahoma, Pennsylvania, and Virginia.

    The above-mentioned product is a live Marek's disease serotype 3 vaccine virus containing a gene from the Newcastle disease virus. The attenuated vaccine is intended for use in healthy 18-day-old or older embryonated eggs or day-old chickens, as an aid in the prevention of Marek's disease and Newcastle disease.

    The EA has been prepared in accordance with: (1) The National Environmental Policy Act of 1969 (NEPA), as amended (42 U.S.C. 4321 et seq.), (2) regulations of the Council on Environmental Quality for implementing the procedural provisions of NEPA (40 CFR parts 1500-1508), (3) USDA regulations implementing NEPA (7 CFR part 1b), and (4) APHIS' NEPA Implementing Procedures (7 CFR part 372).

    Unless substantial issues with adverse environmental impacts are raised in response to this notice, APHIS intends to issue a finding of no significant impact (FONSI) based on the EA and authorize shipment of the above product for the initiation of field tests following the close of the comment period for this notice.

    Because the issues raised by field testing and by issuance of a license are identical, APHIS has concluded that the EA that is generated for field testing would also be applicable to the proposed licensing action. Provided that the field test data support the conclusions of the original EA and the issuance of a FONSI, APHIS does not intend to issue a separate EA and FONSI Start Printed Page 19956to support the issuance of the product license, and would determine that an environmental impact statement need not be prepared. APHIS intends to issue a veterinary biological product license for this vaccine following completion of the field test provided no adverse impacts on the human environment are identified and provided the product meets all other requirements for licensing.

    Start Authority

    Authority: 21 U.S.C. 151-159.

    End Authority Start Signature

    Done in Washington, DC, this 8th day of April 2015.

    Kevin Shea,

    Administrator, Animal and Plant Health Inspection Service.

    End Signature End Supplemental Information

    [FR Doc. 2015-08602 Filed 4-13-15; 8:45 am]

    BILLING CODE 3410-34-P

Document Information

Published:
04/14/2015
Department:
Animal and Plant Health Inspection Service
Entry Type:
Notice
Action:
Notice of availability.
Document Number:
2015-08602
Dates:
We will consider all comments that we receive on or before May 14, 2015.
Pages:
19955-19956 (2 pages)
Docket Numbers:
Docket No. APHIS-2015-0002
PDF File:
2015-08602.pdf
Supporting Documents:
» Risk Analysis -- Marek’s Disease-Newcastle Disease Vaccine, Serotype 3, Live Marek’s Disease Vector
» Environmental Assessment For Field Testing of a Marek’s Disease – Newcastle Disease Vaccine, Serotype 3, Live Marek’s Disease Vector